Vision Impairment News and Research RSS Feed - Vision Impairment News and Research

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Oraya Therapeutics Inc. announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone. [More]
Lifestyle factors modify vision impairment risk

Lifestyle factors modify vision impairment risk

Smoking, drinking alcohol and physical activity are modifiable behaviours that influence the risk of vision impairment, show findings from the Beaver Dam Eye Study. [More]
Research: New ways to help visually impaired better navigate everyday life

Research: New ways to help visually impaired better navigate everyday life

Visual impairment comes in many forms, and it's on the rise in America. A University of Cincinnati experiment aimed at this diverse and growing population could spark development of advanced tools to help all the aging baby boomers, injured veterans, diabetics and white-cane-wielding pedestrians navigate the blurred edges of everyday life. [More]

Digital reading system opens up new educational opportunities for people with vision impairment

People who are blind can now read more than just words, such as graphs and graphics, following the development of an affordable digital reading system by Curtin University researchers. [More]
Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. [More]
Shire intends to submit NDA for lifitegrast to treat dry eye disease

Shire intends to submit NDA for lifitegrast to treat dry eye disease

Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work. [More]
Restoring vision in patients with retinitis pigmentosa: an interview with Dr. Gregoire Cosendai, Vice President, Europe, Second Sight

Restoring vision in patients with retinitis pigmentosa: an interview with Dr. Gregoire Cosendai, Vice President, Europe, Second Sight

Retinitis pigmentosa (RP) is a progressive eye disease that leads to untreatable blindness. The name of the disease derives from the fact that one of the areas affected by the disease is the retinal pigment epithelium (RPE) in the back of the eye. [More]
Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia and Alimera Sciences. [More]
Ethics experts issue decision-making guidelines to aid NASA for higher risk human spaceflights

Ethics experts issue decision-making guidelines to aid NASA for higher risk human spaceflights

Nearly two years after the conclusion of its space shuttle program left Americans wondering what would become of the spacefaring dreams of decades past, NASA has sought the advice of health and ethics experts for protecting astronauts on its "next generation" of long duration and exploration-class human spaceflights. [More]
Alimera Sciences resubmits New Drug Application for ILUVIEN

Alimera Sciences resubmits New Drug Application for ILUVIEN

Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA). [More]
SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for use within the National Health Service Scotland under a simple patient access scheme. [More]
Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients. [More]
Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients. With this new knowledge, investigators aim to accelerate the process of healing and repair in damaged corneas to ultimately reverse the effects of diabetes-induced eye complications. [More]
People with diabetes at risk of developing diabetic macular edema during their lifetime

People with diabetes at risk of developing diabetic macular edema during their lifetime

Despite recent advances in prevention and treatment of most vision loss attributed to diabetes, a new study shows that fewer than half of Americans with damage to their eyes from diabetes are aware of the link between the disease and visual impairment, and only six in 10 had their eyes fully examined in the year leading up to the study. [More]
Researchers investigate several non-invasive methods for measuring intracranial pressure

Researchers investigate several non-invasive methods for measuring intracranial pressure

Do you ever turn your world upside down by standing on your head? After a few minutes you might feel some pressure in your face and around your skull. This is because headstands invert the body's blood flow, pushing more blood toward your head. [More]
Study finds way to regulate sleep patterns of children with brain disorders

Study finds way to regulate sleep patterns of children with brain disorders

For parents of children with brain disorders or visual impairment, nights can be long and frustrating, leading to even more difficult days as exhaustion takes hold. [More]

Alimera Sciences receives Complete Response Letter for New Drug Application from FDA

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug Administration (FDA). [More]
Retinitis pigmentosa test identifies mutation found in Ashkenazi Jewish population

Retinitis pigmentosa test identifies mutation found in Ashkenazi Jewish population

You might not think to look to a urine test to diagnose an eye disease. But a new Duke University study says it can link what is in a patient's urine to gene mutations that cause retinitis pigmentosa, or RP, an inherited, degenerative disease that results in severe vision impairment and often blindness. The findings appear online in the Journal of Lipid Research. [More]
Increasing eye patching is effective at treating persistent amblyopia in children

Increasing eye patching is effective at treating persistent amblyopia in children

The standard treatment for amblyopia, a condition of poor vision in an otherwise healthy eye, is patching: covering a child's better-seeing eye with a patch for two hours a day to improve vision in the weaker eye. [More]
Study: People with cataract-related vision loss who undergo cataract surgery live longer

Study: People with cataract-related vision loss who undergo cataract surgery live longer

People with cataract-related vision loss who have had cataract surgery to improve their sight are living longer than those with visual impairment who chose not to have the procedure, according to an Australian cohort study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology. After comparing the two groups, the researchers found a 40 percent lower long-term mortality risk in those who had the surgery. [More]